Loading...
•
Jun 30
BD Q3 2025 Earnings Report
BD reported strong third quarter fiscal 2025 financial results, with significant increases in revenue, GAAP and adjusted diluted EPS, and operating income, driven by BD Excellence initiatives.
Key Takeaways
BD delivered a robust performance in the third quarter of fiscal 2025, with total revenues reaching $5.51 billion, marking a 10.4% increase year-over-year. Both GAAP and adjusted diluted EPS saw substantial growth, reaching $2.00 and $3.68 respectively. The company's operating income surged by 46.6%, reflecting strong operational efficiency and the positive impact of BD Excellence. BD also raised its full-year adjusted diluted EPS guidance, underscoring confidence in its continued financial performance.
Total revenues for Q3 fiscal 2025 increased by 10.4% to $5.509 billion, compared to $4.990 billion in the prior year.
GAAP diluted EPS grew by 19.0% to $2.00, while adjusted diluted EPS increased by 5.1% to $3.68.
Operating income saw a significant rise of 46.6% to $882 million, up from $602 million in Q3 fiscal 2024.
The company raised its full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an $0.18 increase at the midpoint.
BD
BD
BD Revenue by Segment
BD Revenue by Geographic Location
Revenue by Segment
BD Medical Revenue
CapyFin.comBD Life Sciences Revenue
CapyFin.comBD Interventional Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
BD raised its full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an $0.18 increase to 9.4% growth at the midpoint, while reaffirming organic revenue growth guidance of 3.0% to 3.5%.
Positive Outlook
- Raised full-year adjusted diluted EPS guidance to $14.30 to $14.45.
- Midpoint of adjusted diluted EPS guidance reflects a 9.4% growth.
- Reaffirmed organic revenue growth guidance of 3.0% to 3.5%.
- Expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025.
- Anticipates translational foreign currency to be an increase of approximately $10 million to revenue year over year.
Challenges Ahead
- Incremental investments in selling and marketing in Q4 may impact short-term profitability.
- The impact and timing of potential charges or gains for GAAP measures are uncertain and difficult to predict.
- Foreign currency translation impact is expected to be about neutral to adjusted EPS.
- The proposed combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation is subject to completion risks.
- International trade policies, trade restrictions, and tariffs are rapidly evolving, posing potential risks to guidance and results.